Wechselwirkungen · Duloxetine Viatris (previously Duloxetine Mylan)
Duloxetine Viatris 30 mg hard gastro-resistant capsules Duloxetine Viatris 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 9
HOS-222399 · Präparat HOS-217008
Anticoagulants and antiplatelet agents Caution should be exercised when duloxetine is combined with oral anticoagulants or antiplatelet agents due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction. Furthermore, increases in INR values have been reported when duloxetine was co-administered to patients treated with warfarin. However, concomitant administration of duloxetine with warfarin under steady state conditions, in healthy volunteers, as part of a clinical pharmacology study, did not result in a clinically significant change in INR from baseline or in the pharmacokinetics of R- or S-warfarin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:14:00Z · SHA-256 849b6af2c95c6705cc45837c42b193185a492dbfcd71e17a9b8c6a9dcee13f38 · Passage b20fcb701662e7fe80ad2bd884564adfc396226e00185d2b745d3f743ff1da03 · Zeichen 3500–4141 im Abschnitt